Celiac Research Partnership Builds Takeda’s GI Interests

Takeda continues to expand its interests in the gastrointestinal area through a joint research and development agreement with a small US venture for novel nanoparticle immune modulating therapies for celiac disease.

Takeda Pharmaceutical Co. Ltd. has already said that it sees gastroenterology and gastrointestinal therapies as core interests for its commercial and research portfolio, and the top Japanese pharma firm's latest collaboration bears out this focus.

Takeda has just signed a partnership with the privately held venture Cour Pharmaceutical Development Company to research and develop Cour's...

More from Alimentary/Metabolic

More from Therapy Areas